Nifty
:
15806.15
Sensex
:
52747.98
27.70 (0.18%)
94.91 (0.18%)
Nifty
Sensex
:
:
15806.15
52747.98
27.70 (0.18%)
94.91 (0.18%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
703.00
29-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  687.80
  •  705.95
  •  680.70
  •  687.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4397443
  •  30682.05
  •  721.85
  •  452.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 168,733.23
  • 58.11
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 170,560.56
  • 1.07%
  • 3.63

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 3.22%
  • 7.22%
  • FII
  • DII
  • Others
  • 11.5%
  • 21.47%
  • 2.11%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.08
  • 3.16
  • 7.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.63
  • -3.09
  • 4.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.59
  • -3.62
  • 21.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 40.96
  • 34.69
  • 39.48

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.84
  • 3.24
  • 2.79

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.82
  • 15.78
  • 15.79

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
8,522.98
8,184.94
4.13%
8,836.78
8,154.85
8.36%
8,553.13
8,123.35
5.29%
7,585.25
8,374.36
-9.42%
Expenses
6,474.54
6,821.93
-5.09%
6,502.27
6,395.25
1.67%
6,359.85
6,342.11
0.28%
5,820.90
6,446.13
-9.70%
EBITDA
2,048.44
1,363.01
50.29%
2,334.51
1,759.60
32.67%
2,193.28
1,781.24
23.13%
1,764.35
1,928.23
-8.50%
EBIDTM
24.03%
16.65%
26.42%
21.58%
25.64%
21.93%
3.55%
3.55%
Other Income
111.00
102.23
8.58%
386.58
201.68
91.68%
255.78
209.35
22.18%
232.95
280.40
-16.92%
Interest
30.10
51.78
-41.87%
26.10
62.96
-58.55%
33.28
83.93
-60.35%
51.95
104.06
-50.08%
Depreciation
553.49
575.38
-3.80%
531.94
546.99
-2.75%
498.60
473.28
5.35%
495.92
457.13
8.49%
PBT
903.04
577.44
56.39%
2,163.05
1,351.33
60.07%
1,917.18
1,433.38
33.75%
15.41
15.41
0.00%
Tax
55.04
83.09
-33.76%
244.94
327.62
-25.24%
-31.20
266.03
-
1.10
1.10
0.00%
PAT
848.00
494.35
71.54%
1,918.11
1,023.71
87.37%
1,948.38
1,167.35
66.91%
14.31
14.31
0.00%
PATM
9.95%
6.04%
21.71%
12.55%
22.78%
14.37%
37.11%
37.11%
EPS
3.73
1.67
123.35%
7.72
3.81
102.62%
7.56
4.43
70.65%
1.69
1.69
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
Net Sales Growth
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
 
Cost Of Goods Sold
6,742.74
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
Gross Profit
26,755.40
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
GP Margin
79.87%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
Total Expenditure
25,157.56
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
Power & Fuel Cost
-
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
% Of Sales
-
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
Employee Cost
-
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
% Of Sales
-
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
Manufacturing Exp.
-
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
% Of Sales
-
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
General & Admin Exp.
-
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
% Of Sales
-
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
Selling & Distn. Exp.
-
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
% Of Sales
-
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
Miscellaneous Exp.
-
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
372.14
% Of Sales
-
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
EBITDA
8,340.58
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
EBITDA Margin
24.90%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
Other Income
986.31
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
Interest
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
Depreciation
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
PBT
4,998.68
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
Tax
269.88
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
Tax Rate
5.40%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
PAT
4,728.80
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
PAT before Minority Interest
4,589.64
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
Minority Interest
-139.16
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
PAT Margin
14.12%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
PAT Growth
75.16%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
 
EPS
19.71
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46
11.08
7.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
Share Capital
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
Total Reserves
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
Non-Current Liabilities
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
Secured Loans
257.49
109.47
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
Unsecured Loans
1,771.43
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
Long Term Provisions
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
Current Liabilities
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
Trade Payables
4,093.73
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
Other Current Liabilities
1,891.11
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
Short Term Borrowings
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
Short Term Provisions
4,172.21
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
Total Liabilities
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
Net Block
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
Gross Block
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
Accumulated Depreciation
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
Non Current Assets
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
Capital Work in Progress
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
Non Current Investment
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
Long Term Loans & Adv.
4,060.77
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
Other Non Current Assets
49.24
21.96
50.21
682.18
953.34
103.94
34.20
42.90
18.71
27.75
Current Assets
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
Current Investments
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
Inventories
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
Sundry Debtors
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
Cash & Bank
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
Other Current Assets
2,973.02
1,266.30
891.31
718.25
2,847.64
5,026.16
3,774.42
1,149.11
1,136.55
910.32
Short Term Loans & Adv.
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
Net Current Assets
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
Total Assets
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
PBT
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
Adjustment
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
Changes in Working Capital
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
Cash after chg. in Working capital
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
Net Fixed Assets
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
Net Investments
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
Others
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
Cash from Financing Activity
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
Net Cash Inflow / Outflow
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
Opening Cash & Equivalents
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
Closing Cash & Equivalent
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
59.08
45.79
ROA
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
ROE
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
ROCE
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
Fixed Asset Turnover
1.78
1.92
1.99
1.29
1.34
1.79
1.70
1.51
1.38
1.44
Receivable days
56.22
54.10
53.53
83.25
76.12
48.20
51.72
71.46
71.49
71.57
Inventory Days
48.40
47.84
48.88
78.98
77.46
57.99
63.92
74.22
80.31
80.48
Payable days
63.32
77.81
90.19
85.47
75.24
52.05
56.33
65.15
64.51
51.06
Cash Conversion Cycle
41.30
24.13
12.23
76.75
78.34
54.14
59.31
80.53
87.29
100.98
Total Debt/Equity
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
Interest Cover
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Sun Pharmaceutical, Cassiopea SpA sign license, supply agreements for Winlevi
    26th Jul 2021, 11:14 AM

    Under the terms of the above referred agreements, Sun Pharma will have the exclusive right to commercialize Winlevi in the United States and Canada

    Read More
  • Sun Pharmaceutical launches special initiative ‘Sunkalp’ for welfare of doctors
    1st Jul 2021, 11:08 AM

    To recognise and care for their health & well-being, on the occasion of National Doctors' Day, Sun Pharma launches multifaceted initiatives under Sunkalp

    Read More
  • Sun Pharma enters patent litigation settlement with Celgene for launch of generic Revlimid
    22nd Jun 2021, 10:10 AM

    The license will allow Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026

    Read More
  • Sun Pharmaceutical Industries eyeing biosimilars to fuel its future growth
    14th Jun 2021, 14:45 PM

    The company has no immediate plans to enter into vaccine production

    Read More
  • Sun Pharma’s arm enters into license agreement with Ferring Pharmaceuticals
    2nd Jun 2021, 14:25 PM

    CARITEC is indicated for the prevention of excessive bleeding in women after vaginal or caesarean child birth

    Read More
  • Sun Pharm acquires rights to trademarks of 3 diabetes drug brands in India from AstraZeneca
    28th May 2021, 16:06 PM

    The company has also taken a patent license to manufacture and commercialise Dapagliflozin and Dapagliflozin with Metformin combination in India

    Read More
  • Sun Pharma signs voluntary licensing agreement with Eli Lilly
    10th May 2021, 13:32 PM

    The drug is approved by the Central Drugs Standard Control Organization for restricted emergency use in India

    Read More
  • Sun Pharma recalls 13,834 bottles of diabetes drug ‘Riomet’ in US market
    26th Apr 2021, 09:00 AM

    The affected lot has been distributed in the US by New Jersey-based Sun Pharmaceutical Industries Inc

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.